Clinical Trial Update: The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update for oral LPCN 1144 in nonalcoholic steatohepatitis (NASH) has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• LPCN 1144

Snippet

Sponsor: Lipocine Inc. | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2023-12-14